Posts Tagged ‘omega3 heart disease’

BENEFICIAL EFFECT OF EICOSAPENTAENOIC ACID ON ENDOTHELIAL FUNCTION IN OLD MYOCARDIAL INFARCTION PATIENTS UNDER ADEQUATE STATIN THERAPY

Sunday, April 29th, 2012

BENEFICIAL EFFECT OF EICOSAPENTAENOIC ACID ON ENDOTHELIAL FUNCTION IN OLD MYOCARDIAL INFARCTION PATIENTS UNDER ADEQUATE STATIN THERAPY

Kentaro Toyama, Osamu Sasaki, Toshihiko Nishioka and Hiroyuki Ito
Department of cardiology, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan

J Am Coll Cardiol, 2012; 59:1773, doi:10.1016/S0735-1097(12)61774-4
© 2012 by the American College of Cardiology Foundation

Eicosapentaenoic acid (EPA) is reported to augment endothelial function and improve clinical outcomes in patients with coronary artery disease. However, it is unclear whether the effect of EPA is preserved even in patients under adequate statin therapy as secondary prevention. We hypothesized that EPA could improve endothelial function in old myocardial patients (OMI) with adequate lipid-lowering treatment using statin.
Fifty-five OMI patients under statin treatment with serum LDL cholesterol levels less than 100 mg/dl were randomly assigned to receive either 1800 mg of EPA daily with statin (EPA group, n=29) or statin alone (non-EPA group, n=26). Lipid profiles and flow-mediated dilation (FMD) were assessed just before and 6 months after the randomization in both groups.

EPA group presented significant increase in plasma concentrations of EPA (p<0.001). In EPA group, LDL-cholesterol and trygliceride levels significantly decreased (p<0.05), whereas no significant change was seen in non-EPA group. FMD, which is the primary end point of this study, showed significant improvement in EPA group (2.41±1.46% to 3.18±1.82%, p=0.001), while no significant change was seen in non-EPA group (2.51±1.48% to 2.25±1.42%, p=NS). Furthermore, FMD defined as post FMD - pre FMD significantly increased in EPA group (0.77±1.17 vs –0.25±1.59, p=0.009).

EPA further improved endothelial function in old myocardial infarction patients under adequate statin therapy.

Effect of dietary fish oil on atrial fibrillation after cardiac surgery.

Saturday, September 10th, 2011

Effect of dietary fish oil on atrial fibrillation after cardiac surgery.

Source

Discipline of Medicine, University of Adelaide, Adelaide, Australia.

Abstract

An open-label study reported that ingestion of a fish oil concentrate decreased the incidence of atrial fibrillation (AF) after coronary artery bypass grafting (CABG) surgery. However, a general cardiac surgery population involves valve and CABG surgeries. We undertook a double-blinded randomized controlled trial to examine the effectiveness of fish oil supplementation on the incidence of postsurgical AF after CABG and valve procedures. The primary end point was incidence of AF in the first 6 days after surgery. Two hundred patients were randomized to receive fish oil (providing 4.6 g/day of long-chain ω-3 fatty acids) or a control oil starting 3 weeks before surgery; 194 subjects completed the study, with 47 of 97 subjects in the control group and 36 of 97 subjects in the fish oil group developing AF (odds ratio 0.63, 95% confidence interval [CI] 0.35 to 1.11). There was a nonstatistically significant delay in time to onset of AF in the fish oil group (hazard ratio 0.66, 95% CI 0.43 to 1.01). There was a significant decrease in mean length of stay in the intensive care unit in the fish oil group (ratio of means 0.71, 95% CI 0.56 to 0.90). In conclusion, in a mixed cardiac surgery population, supplementation with dietary fish oil did not result in a significant decrease in the incidence of postsurgical AF. However, there was a significant decrease in time spent in the intensive care unit.

Great Britain Flag
Made in the UK - Take Omega 3 Suspendisse lacinia ultricies justo, at ultricies nisi tempus ac. Cras sed vehicula metus. Phasellus...